P1, N=86, Completed, Bio-Thera Solutions | Recruiting --> Completed | N=42 --> 86

P2, N=90, Not yet recruiting, Kahr Bio Australia Pty Ltd

CD47-targeted combinations demonstrate encouraging early phase efficacy and manageable safety in hematologic malignancies, with signals of benefit in higher-risk MDS, TP53-mutant AML, relapsed/refractory DLBCL, and rituximab-refractory iNHL. However, recent Phase III trials in newly diagnosed AML Daver et al. [27], and Zeidner et al. [26] did not confirm this benefit, underscoring that CD47 blockade remains investigational and requires validation in rigorously designed randomized studies.

Hu5F9-G4 demonstrates potential as a therapeutic agent in CRC by promoting M2d-to-M1 macrophage polarization, suppressing tumor progression, and influencing the autophagy pathway. These findings highlight CDKN1A and MAP1LC3B as promising targets for CRC therapy.

P1, N=25, Terminated, Kahr Medical | N=36 --> 25 | Trial completion date: Jun 2025 --> Oct 2025 | Active, not recruiting --> Terminated; Slow enrolment

P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

Introduction In this preclinical human immune system patient-derived xenograft (HIS PDX) model and phase II clinical trial, we assessed evorpacept (anti-CD47 engineered fusion protein with inactive Fc), cetuximab, and pembrolizumab (triple therapy) in microsatellite stable colorectal cancer (MSS CRC). Conclusions While triple therapy demonstrated evidence of efficacy in refractory MSS CRC, safety concerns halted enrollment. Further investigation is necessary to determine the optimal use of CD47-targeted therapies in MSS CRC.

P1/2, N=24, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=70 --> 24 | Trial completion date: Sep 2028 --> Mar 2026 | Trial primary completion date: Sep 2026 --> Mar 2026

P2, N=254, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting

P1/2, N=40, Recruiting, Chang Gung Memorial Hospital

P1/2, N=25, Terminated, Centessa Pharmaceuticals (UK) Limited | Trial completion date: Jan 2027 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2025 --> Jan 2025; Sponsor terminated the study due to non-safety reasons. Based on the data and the current competitive landscape, Sponsor made the decision to close the study.

To further counter immune evasion, we encapsulated the CD47/SIRPα inhibitor RRX-001 into reactive oxygen species (ROS)-responsive carriers, yielding RRX@RCD...In CT26 tumor-bearing mice, RRX@RCD achieved superior tumor regression, doubled median survival. Overall, RRX@RCD synchronizes innate and adaptive immune activation, offering a safe and potent nanomedicine strategy for durable antitumor immunity.